Get startedLog in
    Picture of Quest PharmaTech logo

    QPT — Quest PharmaTech News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapNeutral
    All News

    Brief: Oncovent initiates clinical development program for anti-MUC1 MAb AR20.5 for treatment of pancreatic cancer

    Picture of Quest PharmaTech logoQuest PharmaTech
    02/11/2016 13:31
    Nov 2 (Reuters) - Quest Pharmatech Inc  QPT.V : 
    * Oncovent initiates clinical development program for 
anti-MUC1 MAb AR20.5 for treatment of pancreatic cancer 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nCNWBwNNpa 
Further company coverage:  QPT.V  
 
 ((Bangalore.newsroom@thomsonreuters.com;))

    Recent news on Quest PharmaTech

    See all news